J&J to Pay Up to $5.5B to Settle Talc Suits; Shares Rise 1.9% After Hours
JNJ sits 64% above its 52-week low of $164.23.
Summary
Johnson & Johnson agreed to pay up to $5.5 billion to resolve remaining ovarian cancer talc lawsuits, with up to $3 billion due in 2027 and no further payments before 2028. The settlement is conditioned on 95% claimant participation, and plaintiffs acknowledged they cannot prove specific causation — a key legal concession that reduces future liability risk. This follows the earlier report of the proposed settlement and adds concrete payment terms and the causation admission. Shares rose 1.9% after hours to $270.88, reflecting relief that the long-running litigation is nearing resolution on manageable terms. The deal removes a major overhang, though finalization depends on claimant opt-in rates.
At the time of this announcement, JNJ was trading at $268.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $640.9B. The 52-week trading range was $164.23 to $269.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.